Phathom is a commercial-stage GI company using VOQUEZNA’s growing revenue base to expand the product beyond its current approved uses, including daily treatment for non-erosive GERD. Its recent strategy has emphasized gastroenterologists, cost control, and building toward profitability while developing additional VOQUEZNA indications.
The filing turns a previously announced plan into an active registrational study. Patient screening has begun in pHalcon-NERD-302, a Phase 3 trial testing VOQUEZNA 10 mg on demand for non-erosive GERD. The direction was already telegraphed in Phathom’s July 2026 business update, so the milestone is partly known rather than a fresh strategic surprise.
The potential expansion is commercially meaningful, but the value remains conditional on a long-dated clinical readout. The study is designed to support a label expansion for as-needed treatment if successful, building on positive Phase 2 results. It will enroll approximately 500 patients across roughly 80 U.S. sites, with a primary endpoint measuring complete relief within two hours and sustained relief for 24 hours after dosing. 〔0〕 〔1〕
The immediate business impact is limited because there is no efficacy, regulatory, or revenue update. Topline results are expected in the first quarter of 2028, leaving the current commercial story unchanged while adding a possible future dosing option and label expansion. 〔2〕
Bottom line: This is execution progress on a previously flagged VOQUEZNA expansion, not a clinical de-risking event. It modestly advances Phathom’s pipeline story, but the meaningful business test remains the 2028 Phase 3 result.
Read the original 8-K on SEC EDGAR ↗